Good Stock To Buy Now: Antares Pharma (AMEX: AIS )

The stock market and picking good stocks to buy now may be quantified in numbers. But, in its purest form, it’s about philosophies. When deciding which stock is the best stock to buy now, whether it’s a penny stock or blue chip, you should be greedy in your intake of information to Aim for the High Profits.

Stock market investing is about coming across sketches of a financial plan that lead to the investigation of companies which ends up on finally determining which one, or ones, to make investment in – or not. These ideas can be spawned by reading newspapers, magazines, and internet articles, scanning share market tables or just picking up the phone and talking to your stockbroker.

The most popular approach for the 21st century is to take out a subscription to a financial newsletter. offers a “FREE” subscription to receiving news and alerts on the “hottest penny stocks” in the stock market today.

In choosing good stocks to buy now, one tried and true method for many of the most profitable traders has been monitoring the analyst ratings; most especially the upgraded stocks and newly covered stocks with positive ratings issued to them.

If you are unsure about how to understand Analysts Ratings, check our post to get a better understanding on spotting good stocks to buy now.

The following penny stock is under $3 and received upgrade to a “buy” rating from one of the top Wall Street analysts Wednesday, February 1, 2012 and would all be considered good stock to buy:

Fundamental company data provided by Capital IQ:

Antares Pharma, Inc. (AMEX: AIS )

AIS closing price for Wednesday, February 1, 2012 was $2.63, up 2.73% (+0.07).
AIS has a 52-week high of $2.88 and a 52-week low of $1.50.
AIS has a 1-Yr Target Price of $3.00 with a Market Cap of $272.24M.
AIS was upgraded by analysts at Roth Capital from a “neutral” rating to a “buy” rating.

January 16, 2012, Antares Pharma, Inc. announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd., for marketing in South Korea. Antares will receive undisclosed upfront payments, regulatory milestones and sales based milestones, as well as royalties on net sales for the product.

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. AIS offers injection devices, which include Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Medi-Jector Vision for insulin; Vibex disposable pressure assisted auto injectors that enables a controlled pressure delivery of drugs into the body utilizing a spring power source; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges.

AIS also provides Anturol, an oxybutynin ATD (advanced transdermal delivery) gel, which is in Phase III clinical trials for the treatment of overactive bladder; Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction; and Nestorone contraceptive formulation products, which has completed Phase II clinical trials.

Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe. It has collaborative arrangements and license agreements with Teva Pharmaceutical Industries, Ltd.; Ferring Pharmaceuticals BV; JCR Pharmaceuticals Co., Ltd.; BioSante Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Population Council.

Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett

If you really want to make some considerable profits from the stock market, it is possible to make a considerable amount of money on penny stock trading. When you find the right penny stock to buy, knowing when to buy and sell is the second most important tool to maximizing your profits.

Being technical, analytical or just flat-out greedy when trading penny stocks is the easiest way to limit profits and, sometimes, even lose your entire investment. You need to have a strong and strict strategy to achieve your goal of maximizing profits while minimizing risks in penny stocks.

Listed below are a few of the many points each and every penny stock investor needs to discover.

  • Do your own research.
  • Trade Responsibly.
  • Verify everything.
  • Move Fast or Get Left Behind.
  • Do not use market orders to enter a position, use limit orders.
  • Have a System That fits You.
  • If a Stock Gaps Open, Look for Pullbacks to Enter.
  • Plan a Trade and Trade a Plan.
  • Always use stop loss orders to protect yourself.
  • Positive Self- Belief.
  • Keep trading as Part of a Balanced life.
  • If a stock breaks below our alert price GET OUT. Do not wait.
  • View Trading as a Score in Points and Not In Money:
  • Always take your profits whenever you can. Do Not Be Greedy.
  • Work Hard at Learning How to Trade Properly and Keep Working.
  • Do something to make someone else’s life better today.

About strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential.

Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.

We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.

Aim High Profits Disclaimer

This is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Kelevra Media Innovation.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision.

Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

For a complete explanation, please visit our disclaimer page.

Last updated by at .

  Recent Penny Stock News